Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study
- 22 July 2019
- journal article
- research article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 20 (2) , 161-168
Abstract
Background Idarucizumab reverses the anticoagulant effect of dabigatran, but few comparative studies have reported on clinical outcomes with idarucizumab. Objective Our objective was to determine the effect of idarucizumab on clinical outcomes. Methods We conducted a retrospective cohort study in a nationally representative sample of hospitals in the United States. The study population included adults ≥ 18 years who were hospitalized for dabigatran-associated major bleeding between January 1, 2015 and December 31, 2017. We compared idarucizumab-exposed patients to the unexposed group. Our primary outcome of interest was in-hospital mortality. Results We included 266 exposed and 1345 non-exposed participants across 271 hospitals. Among participants with gastrointestinal bleeding, there was no statistically significant difference in the odds of in-hospital mortality [9/153 (5.9%) vs 37/1124 (3.3%); adjusted odds ratio = 1.39, 95% confidence interval 0.51–3.45] between the idarucizumab-exposed and non-exposed groups. Among participants with intracranial bleeding, there was an excess of in-hospital mortality [13/112 (11.6%) vs 6/217 (2.8%)] associated with idarucizumab exposure, but limitations include sparse data and the inability to rule out residual confounding or confounding by disease severity. Conclusions Among a large nationally representative sample of adult patients with dabigatran-associated major bleeding in the United States, we found no difference in in-hospital mortality among patients with gastrointestinal bleeding associated with idarucizumab exposure. An excess risk of in-hospital mortality associated with idarucizumab exposure among participants with intracranial bleeding deserves further exploration.Keywords
This publication has 29 references indexed in Scilit:
- Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialThe Lancet, 2015
- Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort studyBMJ, 2015
- Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort studyBMJ, 2015
- Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the USJournal of Medical Economics, 2015
- Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulantsThrombosis and Haemostasis, 2015
- Thrombolysis in a Stroke Patient on Dabigatran Anticoagulation: Case Report and Synopsis of Published CasesCase Reports in Neurology, 2013
- Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the USJournal of Hospital Medicine, 2012
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- An automated database case definition for serious bleeding related to oral anticoagulant usePharmacoepidemiology and Drug Safety, 2011
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005